Glaucoma: Treat to restore vision and comfort in horses
Glaucoma is an emerging disease in horses. Until recently it was thought to be quite rare, but better and more available methods to measure intraocular pressure (IOP) demonstrate that glaucoma is not so uncommon.
Management of glaucoma requires control of both IOP and any underlying process, either by chronic use of topical or systemic drugs or surgery. Damage from glaucoma does not immediately halt with IOP reduction. The neurosensory retina is a delicate nine-layer sheet that contains photoreceptors, other short connecting nerves that collate and modify photoreceptor output and signal the retinal ganglion cells (RGCs), which chemically transmit perception of light to the midbrain and visual centers of the cortex.RGC death Glaucoma results in malfunction and death of RGCs in particular. All RGCs are not equally susceptible, and those with larger axons die early. Greater losses of RGCs diminish vision but central RGCs are more important than those peripherally. The pathogenesis of death involves release of chemical mediators (glutamate) and inadequate blood flow. Destruction spreads as toxic mediators are released from decaying neurons, injuring adjacent cells.
If aggressive therapy is desired and pursued, and the uveitis becomes contained, vision may be restored despite substantial retinal damage and sequelae. The prognosis is certainly poorer if uveitis cannot be brought into remission. It is imperative that both globes are fully evaluated prior to selecting a therapeutic plan. Perception of light as a dazzle response or consensual PLR to the contralateral eye are encouraging. If in doubt, a treatment trial is warranted. After two weeks, if vision remains absent or IOP cannot be controlled, comfort and quality of life become primary goals.
Evaluate options Options are continued topical therapy, but compliance is often poor with a blind eye, especially in stoic individuals that show few signs despite clearly substantial disease. Alternative surgical approaches are placement of an ocular prosthesis (intrascleral or hydroxyapatite shell conformer) or more simply by globe removal. Occasionally, intravitreal injection of 25-40 mg of gentamicin is performed under general anesthesia to induce ciliary ablation. This procedure is blinding and unpredictable, with potential complications including persistent uveitis, hyphema, phthisis and endophthalmitis. Ablation forces an IOP reduction but is a poor choice if IOP is not elevated because it is unlikely to improve comfort.
Complete hyphema (Photo 3) induces the most troublesome glaucoma because intense obstruction of the anterior chamber with blood rapidly results in high IOPs, inflammatory membrane formation and intense pain. Aggressive anti-inflammatories (topical steroids, oral NSAIDs) are the key, with close monitoring of IOP and in select cases more aggressive intraocular procedures to minimize sequelae and attempt to salvage vision. The prognosis remains guarded, and the possibility of globe rupture should be investigated.